The company Sinopharm, maker of the coronavirus vaccine being administered in China, has confirmed that the best aged between 3 and 17 years “may soon be vaccinated against the coronavirus.”
The laboratory has conducted a series of clinical investigations that have shown as a result that “The effects of the vaccine in minors are not different from those offered in people between 18 and 59 years old”, as stated by the president of the company, Liu Jingzhen.
The Sinopharm vaccine began to be administered to adults between 18 and 59 years old employed in high-risk professions last July. Nevertheless, It was not until December when it obtained authorization for its emergency use and when, therefore, the population groups that could have access to the population were expanded. Among them were not minors, but “we believe that very soon they will be able to have access to the vaccine”Jingzhen added.
A new vaccine
The Chinese drug regulatory agency is reviewing the efficacy of a new vaccine developed by the Sinopharm Institute for Biologicals in Wuhan, place where the first coronavirus outbreaks were reported in the world. This drug is composed, unlike the one that is already being inoculated, of the “antigen peak protein”, therefore the company assures that its approval would allow to increase production and “massively immunize”.
According to the data of the pharmacist, 43 million doses have been administered worldwide, 34 million of them in China. “We have the capacity to manufacture 1 billion doses,” Jingzhen concluded.
The Sinopharm vaccine will be administered, in addition to China, in countries such as Peru, Argentina, the Philippines, Bolivia, Serbia or Hungary, among others.